• Version
• Download 117
• File Size 361.87 KB
• File Count 2
• Create Date January 9, 2023
• Last Updated January 9, 2023

Special Authority: Empagliflozin and Semaglutide (inj)

Pharmacare now considers SGLT2 and GLP1 (injectable) products as 2nd line diabetes drugs - after Metformin. The attached eFORMS are specific to these products.  Note that approval for a DPP4 product (a separate eFORM needed) cancels approval for either of these and vice versa.

There are two versions - one with a wet signature only (Stan Hurwitz), and one with signature stamp (John Yap) as the default and a wet signature as a back-up option.

Attached Files